Takeda’s Adzynma, BeiGene’s Sonrotoclax, and Avistone’s Andatinib Set for Priority Review in China
The website of China’s Center for Drug Evaluation (CDE) indicates that Takeda’s (TYO: 4502) Adzynma...
Cancer
3SBio’s 707 Bispecific Antibody Receives BTD for First-Line NSCLC in China
China-based 3SBio Inc. (HKG: 1530) has announced the receipt of Breakthrough Therapy Designation (BTD) from...
Shanghai Henlius Initiates Phase II Study of HLX22 in HER2 Low Breast Cancer
China-based Shanghai Henlius Biotech Inc. (HKG: 2696) has announced the first patient dosing in a...
GSK’s Blenrep Approved by UK MHRA for Multiple Myeloma Treatment
UK-based pharmaceutical giant UK-based pharmaceutical company GlaxoSmithKline (GSK, NYSE: GSK) has announced the receipt of...
Hansoh’s HS-20093 ADC Earns BTD for Advanced NSCLC from China’s NMPA
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced that China’s National Medical Products...
Chengdu Kanghong Gains NMPA Approval for KH815 in Advanced Solid Tumors
China-based Chengdu Kanghong Pharmaceutical Group Co., Ltd. (SHE: 002773) has received clinical trial approval from...
Sichuan Biokin Secures Four Phase II Approvals for BL-B01D1 in Combination Therapies
China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced that it has secured four...
Hansoh Pharmaceutical Gains Clinical Approval for KRAS G12D Targeted Drug HS-10529
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced that it has received clinical...
Johnson & Johnson Reports Q1 2025 Revenue Growth, Led by Innovative Medicines and MedTech
US pharmaceutical giant Johnson & Johnson (J&J, NYSE: JNJ) reported Q1 2025 revenues of USD...
Roche’s Columvi Approved by EC for Relapsed DLBCL Treatment in Europe
Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) has announced that it has received marketing...
Zhuhai Beihai Biotech Gains NMPA Clinical Clearance for Innovative Peptide-Drug Conjugate BH259
China-based Zhuhai Beihai Biotech Co., Ltd. has announced that it has received clinical trial clearance...
Bristol-Myers Squibb Wins FDA Approval for Opdivo-Yervoy Combo in First-Line HCC Treatment
Bristol-Myers Squibb (BMS, NYSE: BMY) has secured another indication approval from the US Food and...
Amgen’s Imdelltra Shows Positive Phase III Results in Small Cell Lung Cancer
US biotech giant Amgen (NASDAQ: AMGN) has announced positive results from the global Phase III...
Johnson & Johnson Launches Rybrevant in China for EGFR Exon 20 Insertion Mutation Lung Cancer
US pharmaceutical giant Johnson & Johnson (J&J, NYSE: JNJ) has officially launched Rybrevant (amivantamab), an...
Nona Biosciences and Atossa Therapeutics Forge Partnership to Advance Breast Cancer Therapies
Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a...
Sino Biopharma’s TQB3019 Gains NMPA Approval for Hematological Malignancies
China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced that it has received clinical approval from the...
Sichuan Biokin Launches Phase III Trial for BL-B01D1 in Urothelial Carcinoma
China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced the first patient enrollment in...
Yunnan Baiyao’s INR102 Gains NMPA Clinical Trial Clearance for Prostate Cancer
Yunnan Baiyao Group Co., Ltd (SHE: 000538), a traditional Chinese medicine (TCM) company based in...
CSPC Pharmaceutical’s JMT108 Gains FDA Approval for Advanced Malignant Tumor Trials
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that it has received approval from the...
TJ Biopharma Partners with Biogen on Felzartamab Phase III Studies in China
China-based TJ Biopharma has entered into an agreement with US-based Biogen Inc. (NASDAQ: BIIB) to...